Diagnosing and managing patients with drug hypersensitivity

References

• Pichler WJ. Drug hypersensitivity: classification and clinical features. In: Post TW, editor. UpToDate. Waltham (MA): UpToDate Inc. [Cited 2017 Jun 26]. Available from: http://www.uptodate.com
   Google Scholar
• Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for hypersensitivity for global use: report of the Nomenclature Review Committee of the World Hypersensitivity Organization, October 2003. J Hypersensitivity Clin Immunol. 2004;113:832–836.
   Web of Science ®Google Scholar
• Blanca M, Romano A, Torres MJ, et al. Update on the evaluation of hypersensitivity reactions to betalactams. Hypersensitivity. 2009;64(2):183–193.
   Google Scholar
• Joint Task Force on Practice Parameters; American Academy of Hypersensitivity, Asthma and Immunology; American College of Hypersensitivity, Asthma and Immunology; Joint Council of Hypersensitivity, Asthma and Immunology. Drug hypersensitivity: an updated practice parameter. Ann Hypersensitivity Asthma Immunol. 2010;105(4):259–273.
   PubMed Web of Science ®Google Scholar
• Romano A, Torres MJ, Castells M, et al. Diagnosis and management of drug hypersensitivity reactions. J Hypersensitivity Clin Immunol. 2011 Mar;127(3 Suppl):S67–S73.
   Web of Science ®Google Scholar
• Gaeta F, Torres MJ, Valluzzi RL, et al. Diagnosing β-lactam hypersensitivity. Curr Pharm Des. 2016;22(45):6803–6813.
   PubMed Web of Science ®Google Scholar
• Torres MJ, Barrionuevo E, Kowalski M, et al. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Immunol Hypersensitivity Clin North Am. 2014;34(3):507–524.
   PubMed Web of Science ®Google Scholar
• Pichler WJ. Drug hypersensitivity reactions: classification and relationships to T-cell activation. In: Pichler WJ, editor. Drug hypersensitivity. Basel: Karger; 2007. p. 168–189.
   Google Scholar
• Kowalski ML, Makowska JS. Seven steps to the diagnosis of NSAIDs hypersensitivity: how to apply a new classification in real practice? Hypersensitivity Asthma Immunol Res. 2015;7(4):312–320.
   PubMed Web of Science ®Google Scholar
• Pichler WJ, Hausmann O. Classification of drug hypersensitivity into allergic, p-i, and pseudo-allergic forms. Int Arch Hypersensitivity Immunol. 2016;171(3–4):166–179.
   PubMed Web of Science ®Google Scholar
• Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139(8):683–693.
   PubMed Web of Science ®Google Scholar
• Demoly P, Kropf R, Bircher A, et al. Drug hypersensitivity: questionnaire. EAACI interest group on drug hypersensitivity. Hypersensitivity. 1999;54(9):999–1003.
   Google Scholar
• Messaad D, Sahla H, Benahmed S, et al. Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann Intern Med. 2004;140(12):1001–1006.
   PubMed Web of Science ®Google Scholar
• Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs – an ENDA/EAACI Drug Hypersensitivity Interest Group position paper. Hypersensitivity. 2013;68(6):702–712.
   Google Scholar
• Brockow K, Romano A, Blanca M, et al. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Hypersensitivity. 2002;57(1):45–51.
   Google Scholar
• Ariza A, García-Martín E, Salas M, et al. Pyrazolones metabolites are relevant for identifying selective anaphylaxis to metamizole. Sci Rep. 2016;6:23845.
   PubMed Web of Science ®Google Scholar
• Fernandez TD, Ariza A, Palomares F, et al. Hypersensitivity to fluoroquinolones: the expression of basophil activation markers depends on the clinical entity and the culprit fluoroquinolone. Medicine. 2016;95(23):e3679.
   PubMed Web of Science ®Google Scholar
• Gomez E, Blanca-Lopez N, Torres MJ, et al. Immunoglobulin E-mediated immediate allergic reactions to dipyrone: value of basophil activation test in the identification of patients. Clin Exp Hypersensitivity. 2009;39(8):1217–1224.
   Google Scholar
• Gamboa PM, Sanz ML, Caballero MR, et al. Use of CD63 expression as a marker of in vitro basophil activation and leukotriene determination in metamizol allergic patients. Hypersensitivity. 2003;58(4):312–317.
   Google Scholar
• Kvedariene V, Kamey S, Ryckwaert Y, et al. Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils. Hypersensitivity. 2006;61(3):311–315.
   Google Scholar
• Fernandez TD, Torres MJ, Blanca-Lopez N, et al. Negativization rates of IgE radioimmunoassay and basophil activation test in immediate reactions to penicillins. Hypersensitivity. 2009;64(2):242–248.
   Google Scholar
• Kuruvilla M, Khan DA. Anaphylaxis to drugs. Immunol Hypersensitivity Clin North Am. 2015;35(2):303–319.
   PubMed Web of Science ®Google Scholar
• Fernandez TD, Mayorga C, Salas M, et al. Evolution of diagnostic approaches in betalactam hypersensitivity. Expert Review Clinical Pharmacol. 2017;10(6):671–683.
   PubMed Web of Science ®Google Scholar
• Doña I, Blanca-López N, Torres MJ, et al. Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol. 2012;22(5):363–371.
   PubMed Web of Science ®Google Scholar
• Macy E. Penicillin and beta-lactam hypersensitivity: epidemiology and diagnosis. Curr Allergy Asthma Rep. 2014;14(11):476.
   PubMed Web of Science ®Google Scholar
• Silviu-Dan F, McPhillips S, Warrington RJ. The frequency of skin test reactions to side-chain penicillin determinants. J Hypersensitivity Clin Immunol. 1993;91(3):694–701.
   Web of Science ®Google Scholar
• Romano A, Mayorga C, Torres MJ, et al. Immediate allergic reactions to cephalosporins: cross-reactivity and selective responses. J Hypersensitivity Clin Immunol. 2000;106(6):1177–1183.
   Web of Science ®Google Scholar
• Torres MJ, Romano A, Mayorga C, et al. Diagnostic evaluation of a large group of patients with immediate hypersensitivity to penicillins: the role of skin testing. Hypersensitivity. 2001;56(9):850–856.
   Google Scholar
• Torres MJ, Ariza A, Mayorga C, et al. Clavulanic acid can be the component in amoxicillin-clavulanic acid responsible for immediate hypersensitivity reactions. J Hypersensitivity Clin Immunol. 2010;125(2):502–505.
   Web of Science ®Google Scholar
• Sanchez-Morillas L, Perez-Ezquerra PR, Reano-Martos M, et al. Selective allergic reactions to clavulanic acid: a report of 9 cases. J Hypersensitivity Clin Immunol. 2010;126(1):177–179.
   Web of Science ®Google Scholar
• Lacombe-Barrios J, Salas M, Gomez F, et al. The addition of benzylpenicillin does not increase the skin test sensitivity obtained with classic beta-lactam determinants. J Hypersensitivity Clin Immunol. 2016;26(1):52–54.
   Web of Science ®Google Scholar
• Torres MJ, Blanca M. The complex clinical picture of beta-lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams. Med Clin North Am. 2010;94(4):805–820.
   PubMed Web of Science ®Google Scholar
• Del Real GA, Rose ME, Ramirez-Atamoros MT, et al. Penicillin skin testing in patients with a history of beta-lactam hypersensitivity. Ann Hypersensitivity Asthma Immunol. 2007;98(4):355–359.
   PubMed Web of Science ®Google Scholar
• Caubet JC, Kaiser L, Lemaitre B, et al. The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. J Hypersensitivity Clin Immunol. 2011;127(1):218–222.
   Web of Science ®Google Scholar
• Kamboj S, Yousef E, McGeady S, et al. The prevalence of antibiotic skin test reactivity in a pediatric population. Hypersensitivity Asthma Proc. 2011;32(2):99–105.
   PubMed Web of Science ®Google Scholar
• Macy E, Mangat R, Burchette RJ. Penicillin skin testing in advance of need: multiyear follow-up in 568 test result-negative subjects exposed to oral penicillins. J Hypersensitivity Clin Immunol. 2003;111(5):1111–1115.
   Web of Science ®Google Scholar
• Solley GO, Gleich GJ, Van Dellen RG. Penicillin hypersensitivity: clinical experience with a battery of skin-test reagents. J Hypersensitivity Clin Immunol. 1982;69(2):238–244.
   Web of Science ®Google Scholar
• Macy E, Burchette RJ. Oral antibiotic adverse reactions after penicillin skin testing: multi-year follow-up. Hypersensitivity. 2002;57(12):1151–1158.
   Google Scholar
• Co Minh HB, Bousquet PJ, Fontaine C, et al. Systemic reactions during skin tests with beta-lactams: a risk factor analysis. J Hypersensitivity Clin Immunol. 2006;117(2):466–468.
   Web of Science ®Google Scholar
• Himly M, Jahn-Schmid B, Pittertschatscher K, et al. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J Hypersensitivity Clin Immunol. 2003;111(4):882–888.
   Web of Science ®Google Scholar
• Kowalski ML, Bienkiewicz B, Woszczek G, et al. Diagnosis of pyrazolone drug sensitivity: clinical history versus skin testing and in vitro testing. Hypersensitivity Asthma Proc. 1999;20(6):347–352.
   PubMed Web of Science ®Google Scholar
• Lee QU. Hypersensitivity to antipyretics: pathogenesis, diagnosis, and management. Hong Kong Med J. 2017;23(4):395–403.
   PubMed Web of Science ®Google Scholar
• de Paramo BJ, Gancedo SQ, Cuevas M, et al. Paracetamol (acetaminophen) hypersensitivity. Ann Hypersensitivity Asthma Immunol. 2000;85(6):508–511.
   PubMed Web of Science ®Google Scholar
• Kowalski ML, Makowska JS, Blanca M, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) – classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/HANNA. Allergy. 2011;66:818–829.
   PubMed Web of Science ®Google Scholar
• Rutkowski K, Nasser SM, Ewan PW. Paracetamol hypersensitivity: clinical features, mechanism and role of specific IgE. Int Arch Allergy Immunol. 2012;159:60–64.
   PubMed Web of Science ®Google Scholar
• Del Pozo MD, Lobera T, Blasco A. Selective hypersensitivity to diclofenac. Hypersensitivity. 2000;55(4):412–413.
   Google Scholar
• Moneret-Vautrin DA. Skin tests for diagnosis of curare hypersensitivity. Ann Fr Anesth Reanim. 2002;21(Suppl 1):97s–107s.
   PubMedGoogle Scholar
• Hoffmann HJ, Santos AF, Mayorga C, et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Hypersensitivity. 2015;70(11):1393–1405.
   Google Scholar
• De Week AL, Sanz ML, Gamboa PM, et al. Diagnosis of immediate-type beta-lactam hypersensitivity in vitro by flow-cytometric basophil activation test and sulfidoleukotriene production: a multicenter study. JInvestig Allergol Clin Immunol. 2009;19(2):91–109.
   PubMed Web of Science ®Google Scholar
• Torres MJ, Padial A, Mayorga C, et al. The diagnostic interpretation of basophil activation test in immediate allergic reactions to betalactams. Clin Exp Hypersensitivity. 2004;34(11):1768–1775.
   Google Scholar
• Mayorga C, Celik G, Rouzaire P, et al. In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Hypersensitivity Interest Group position paper. Hypersensitivity. 2016;71(8):1103–1134.
   Google Scholar
• Demoly P, Adkinson NF, Brockow K, et al. International consensus on drug hypersensitivity. Hypersensitivity. 2014;69(4):420–437.
   Google Scholar
• Manfredi M, Severino M, Testi S, et al. Detection of specific IgE to quinolones. J Hypersensitivity Clin Immunol. 2004;113(1):155–160.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Matucci A, Virgili G, et al. Influence of total serum IgE levels on the in vitro detection of beta-lactams-specific IgE antibodies. Clin Exp Hypersensitivity. 2009;39(6):838–844.
   Google Scholar
• Blanca M, Mayorga C, Torres MJ, et al. Clinical evaluation of Pharmacia CAP System RAST FEIA amoxicilloyl and benzylpenicilloyl in patients with penicillin hypersensitivity. Hypersensitivity. 2001;56(9):862–870.
   Google Scholar
• Sanz ML, Gamboa PM, Antepara I, et al. Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics. Clin Exp Hypersensitivity. 2002;32(2):277–286.
   Google Scholar
• Fontaine C, Mayorga C, Bousquet PJ, et al. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam hypersensitivity. Hypersensitivity. 2007;62(1):47–52.
   Google Scholar
• Vultaggio A, Virgili G, Gaeta F, et al. High serum beta-lactams specific/total IgE ratio is associated with immediate reactions to beta-lactams antibiotics. PloS One. 2015;10(4):e0121857.
   PubMed Web of Science ®Google Scholar
• Aranda A, Mayorga C, Ariza A, et al. In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones. Hypersensitivity. 2011;66(2):247–254.
   Google Scholar
• Ebo DG, Venemalm L, Bridts CH, et al. Immunoglobulin E antibodies to rocuronium: a new diagnostic tool. Anesthesiology. 2007;107(2):253–259.
   PubMed Web of Science ®Google Scholar
• Leysen J, Bridts CH, De Clerck LS, et al. Hypersensitivity to rocuronium: from clinical suspicion to correct diagnosis. Hypersensitivity. 2011;66(8):1014–1019.
   Google Scholar
• Rouzaire P, Proton G, Bienvenu F, et al. IgE antibody detection in the diagnosis of hypersensitivity to neuromuscular blocking agents. Acta Anaesthesiol Scand. 2012;56(2):263–264.
   PubMed Web of Science ®Google Scholar
• Laroche D, Chollet-Martin S, Léturgie P, et al. Evaluation of a new routine diagnostic test for immunoglobulin E sensitization to neuromuscular blocking agents. Anesthesiology. 2011;114(1):91–97.
   PubMed Web of Science ®Google Scholar
• Mayorga C, Doña I, Perez-Inestrosa E, et al. The value of in vitro tests to diminish drug challenges. Int J Mol Sci. 2017;18(6):E1222.
   PubMed Web of Science ®Google Scholar
• Romano A, Gueant-Rodriguez R-M, Viola M, et al. Diagnosing immediate reactions to cephalosporins. Clin Exp Allergy. 2005;35:1234–1242.
   PubMed Web of Science ®Google Scholar
• Blanca M, Perez E, Garcia JJ, et al. Angioedema and IgE antibodies to aspirin: a case report. Ann Hypersensitivity. 1989;62:295–298.
   Google Scholar
• Harrer A, Lang R, Grims R, et al. Diclofenac hypersensitivity: antibody responses to the parent drug and relevant metabolites. PloS One. 2010;5(10):e13707.
   PubMed Web of Science ®Google Scholar
• Steiner M, Harrer A, Lang R, et al. Basophil activation test for investigation of IgE-mediated mechanisms in drug hypersensitivity. J Vis Exp. 2011;55:3263.
   Google Scholar
• Ariza A, Montanez MI, Fernandez TD, et al. Cellular tests for the evaluation of drug hypersensitivity. Curr Pharm Des. 2016;22(45):6773–6783.
   PubMed Web of Science ®Google Scholar
• Decuyper II, Mangodt EA, Van Gasse AL, et al. In vitro diagnosis of immediate drug hypersensitivity anno 2017: potentials and limitations. Drugs R D. 2017;17:265–278.
   PubMed Web of Science ®Google Scholar
• Miura K, MacGlashan DW. Phosphatidylinositol-3 kinase regulates p21ras activation during IgE-mediated stimulation of human basophils. Blood. 2000;96(6):2199–2205.
   PubMed Web of Science ®Google Scholar
• Abuaf N, Rostane H, Rajoely B, et al. Comparison of two basophil activation markers CD63 and CD203c in the diagnosis of amoxicillin hypersensitivity. Clin Exp Hypersensitivity. 2008;38(6):921–928.
   Google Scholar
• Monneret G, Benoit Y, Debard AL, et al. Monitoring of basophil activation using CD63 and CCR3 in hypersensitivity to muscle relaxant drugs. Clin Immunol. 2002;102(2):192–199.
   PubMed Web of Science ®Google Scholar
• Uyttebroek AP, Sabato V, Leysen J, et al. Flowcytometric diagnosis of atracurium-induced anaphylaxis. Hypersensitivity. 2014;69(10):1324–1332.
   Google Scholar
• Mayorga C, Andreu I, Aranda A, et al. Fluoroquinolone photodegradation influences specific basophil activation. Int Arch Hypersensitivity Immunol. 2013;160(4):377–382.
   PubMed Web of Science ®Google Scholar
• Rouzaire P, Nosbaum A, Denis L, et al. Negativity of the basophil activation test in quinolone hypersensitivity: a breakthrough for provocation test decision-making. Int Arch Hypersensitivity Immunol. 2012;157(3):299–302.
   PubMed Web of Science ®Google Scholar
• Hagau N, Longrois D, Petrisor C. Threshold for positivity and optimal dipyrone concentration in flow cytometry-assisted basophil activation test. Hypersensitivity Asthma Immunol Res. 2013;5(6):383–388.
   PubMed Web of Science ®Google Scholar
• Ben Said B, Berard F, Bienvenu J, et al. Usefulness of basophil activation tests for the diagnosis of IgE-mediated hypersensitivity to quinolones. Hypersensitivity. 2010;65(4):535–536.
   Google Scholar
• Antunez C, Blanca-Lopez N, Torres MJ, et al. Immediate allergic reactions to cephalosporins: evaluation of cross-reactivity with a panel of penicillins and cephalosporins. J Hypersensitivity Clin Immunol. 2006;117(2):404–410.
   Web of Science ®Google Scholar
• de Weck AL, Sanz ML. Cellular allergen stimulation test (CAST) 2003, a review. J Investig Allergol Clin Immunol. 2004;14(4):253–273.
   PubMed Web of Science ®Google Scholar
• Ebo DG, Leysen J, Mayorga C, et al. The in vitro diagnosis of drug hypersensitivity: status and perspectives. Hypersensitivity. 2011;66(10):1275–1286.
   Google Scholar
• Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Hypersensitivity. 2003;58(9):854–863.
   Google Scholar
• Iammatteo M, Blumenthal KG, Saff R, et al. Safety and outcomes of test doses for the evaluation of adverse drug reactions: a 5-year retrospective review. J Hypersensitivity Clin Immunol Pract. 2014;2:768–774.
   PubMed Web of Science ®Google Scholar
• Demoly P, Romano A, Botelho C, et al. Determining the negative predictive value of provocation tests with beta-lactams. Hypersensitivity. 2010;65(3):327–332.
   Google Scholar
• Bircher AJ. Symptoms and danger signs in acute drug hypersensitivity. Toxicology. 2005;209:201–207.
   PubMed Web of Science ®Google Scholar
• Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol. 2003;2:278–299.
   PubMedGoogle Scholar
• Roujeau J-C. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209:123–129.
   PubMed Web of Science ®Google Scholar
• Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother. 2002;36(1):130–147.
   PubMed Web of Science ®Google Scholar
• Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg. 1996;15:250–257.
   PubMed Web of Science ®Google Scholar
• Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part I. Clinical perspectives. J Am Acad Dermatol. 2013;68:693.e1–714.e1.
   Web of Science ®Google Scholar
• Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part II. Management and therapeutics. J Am Acad Dermatol. 2013;68:709.e1.
   Web of Science ®Google Scholar
• Shiohara T, Kano Y. Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management. Expert Opin Drug Saf. 2017;16:139–147.
   PubMed Web of Science ®Google Scholar
• Roujeau JC. Drug reaction with eosinophilia and systemic symptoms (DRESS). In: Post TW, editor. UpToDate. Waltham (MA): UpToDate Inc. [Cited 2017 Jun 26]. Available from: http://www.uptodate.com
   Google Scholar
• High WA, Nirken MH, Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis: management, prognosis, and long-term sequelae. In: Post TW, editor. UpToDate. Waltham (MA): UpToDate Inc. [Cited 2017 Jun 26]. Available from: http://www.uptodate.com
   Google Scholar
• Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88:60–68.
   PubMed Web of Science ®Google Scholar
• Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149–153.
   PubMed Web of Science ®Google Scholar
• Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology. 2003;206:353–356.
   PubMed Web of Science ®Google Scholar
• Pavlos R, Mallal S, Ostrov D, et al. Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug hypersensitivity. J Hypersensitivity Clin Immunol Pract. 2014;2:21–33.
   PubMed Web of Science ®Google Scholar
• Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428:486.
   PubMed Web of Science ®Google Scholar
• Zhang F-R, Liu H, Irwanto A, et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med. 2013;369:1620–1628.
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–579.
   PubMed Web of Science ®Google Scholar
• Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther. 2009;13:1–9.
   PubMed Web of Science ®Google Scholar
• Hung S-I, Chung W-H, Liou L-B, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102:4134–4139.
   PubMed Web of Science ®Google Scholar
• Yun J, Marcaida MJ, Eriksson KK, et al. Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01. J Immunol. 2014;192:2984–2993.
   PubMed Web of Science ®Google Scholar
• Saito Y, Stamp LK, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2016;99:36–37.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Ostrov DA, Park BK. New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. J Hypersensitivity Clin Immunol. 2015;136(2):236–244.
   Web of Science ®Google Scholar
• Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheumatol. 2015;12:235–242.
   PubMed Web of Science ®Google Scholar
• Solensky R. Penicillin hypersensitivity: delayed hypersensitivity reactions. In: Post TW, editor. UpToDate. Waltham (MA): UpToDate Inc. [Cited 2017 Jun 26]. Available from: http://www.uptodate.com
   Google Scholar
• Torres MJ, Romano A, Celik G, et al. Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America. Clin Transl Hypersensitivity. 2017;7:7.
   Google Scholar
• Lobera T, Padial MA, Guerrero-Garcia MA. Concentrations of active ingredients and excipients used for the performance of skin and epicutaneous tests. In: Davila IJ, Jauregui I, Olaguibel JM, et al., editors. Tratado de Alergología. 2nd ed. Madrid: Ergon; 2016. Spanish.
   Google Scholar
• Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Hypersensitivity Clin Immunol. 2008;122:992–1000.
   Web of Science ®Google Scholar
• Abe R, Yoshioka N, Murata J, et al. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med. 2009;151:514–515.
   PubMed Web of Science ®Google Scholar
• Nakajima S, Watanabe H, Tohyama M, et al. High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome. Arch Dermatol. 2011;147:1110–1112.
   PubMedGoogle Scholar
• Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168:555–562.
   PubMed Web of Science ®Google Scholar
• Kano Y, Hirahara K, Mitsuyama Y, et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Hypersensitivity. 2007;62:1439–1444.
   Google Scholar
• Thong BY, Mirakian R, Castells M, et al. A world hypersensitivity organization international survey on diagnostic procedures and therapies in drug hypersensitivity/hypersensitivity. World Hypersensitivity Organ J. 2011;4:257–270.
   PubMedGoogle Scholar
• Porebski G, Pecaric-Petkovic T, Groux-Keller M, et al. In vitro drug causality assessment in Stevens-Johnson syndrome – alternatives for lymphocyte transformation test. Clin Exp Hypersensitivity. 2013;43:1027–1037.
   Google Scholar
• Muraro A, Roberts G, Worm M, et al. Anaphylaxis: guidelines from the European Academy of Hypersensitivity and Clinical Immunology. Hypersensitivity. 2014;69(8):1026–1045.
   Google Scholar
• Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis – a practice parameter update 2015. Ann Hypersensitivity Asthma Immunol. 2015;115(5):341–384.
   PubMed Web of Science ®Google Scholar
• Shear NH, Knowles SR, Shapiro L. Cutaneous reactions to drugs. In: Wolff K, Goldsmith LA, Katz SI, et al., editors. Fitzpatrick’s dermatology in general medicine. 7th ed. New York (NY): McGraw Hill; 2008. p. 355.
   Google Scholar
• Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69(187):e1–e16.
   PubMedGoogle Scholar
• Schneck J, Fagot J-P, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol. 2008;58:33–40.
   PubMed Web of Science ®Google Scholar
• Zhu Q-Y, Ma L, Luo X-Q, et al. Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China. J Burn Care Res. 2012;33:e295–e308.
   PubMed Web of Science ®Google Scholar
• Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int J Dermatol. 2015;54:108–115.
   PubMed Web of Science ®Google Scholar
• Bamichas G, Natse T, Christidou F, et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher. 2002;6:225–228.
   PubMedGoogle Scholar
• Arévalo JM, Lorente JA, González-Herrada C, et al. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma. 2000;48:473–478.
   PubMedGoogle Scholar
• Reese D, Henning JS, Rockers K, et al. Cyclosporine for SJS/TEN: a case series and review of the literature. Cutis. 2011;87:24–29.
   PubMed Web of Science ®Google Scholar
• Lee HY, Fook-Chong S, Koh HY, et al. Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: retrospective analysis of a cohort treated in a specialized referral center. J Am Acad Dermatol. 2017;76:106–113.
   PubMed Web of Science ®Google Scholar
• Zárate-Correa LC, Carrillo-Gómez DC, Ramírez-Escobar AF, et al. Toxic epidermal necrolysis successfully treated with infliximab. J Investig Allergol Clin Immunol. 2013;23:61–63.
   PubMed Web of Science ®Google Scholar
• Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014;71:278–283.
   PubMed Web of Science ®Google Scholar
• Brockow K, Aberer W, Atanaskovic-Markovic M, et al. Drug hypersensitivity passport and other documentation for patients with drug hypersensitivity – an ENDA/EAACI Drug Hypersensitivity Interest Group position paper. Hypersensitivity. 2016;71(11):1533–1539.
   Google Scholar
• Daubner B, Groux-Keller M, Hausmann OV, et al. Multiple drug hypersensitivity: normal Treg cell function but enhanced in vivo activation of drug-specific T cells. Hypersensitivity. 2012;67(1):58–66.
   Google Scholar
• MacLaughlin EJ, Saseen JJ, Malone DC. Costs of beta-lactam allergies: selection and costs of antibiotics for patients with a reported beta-lactam hypersensitivity. Arch Fam Med. 2000;9(8):722–726.
   PubMedGoogle Scholar
• Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhoea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442–2449.
   PubMed Web of Science ®Google Scholar
• Rao GG. Risk factors for the spread of antibiotic-resistant bacteria. Drugs. 1998;55(3):323–330.
   PubMed Web of Science ®Google Scholar
• Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin “hypersensitivity” in hospitalized patients: a cohort study. J Hypersensitivity Clin Immunol. 2014;133(3):790–796.
   Web of Science ®Google Scholar
• Torres MJ, Blanca M, Fernandez J, et al. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Hypersensitivity. 2003;58(10):961–972.
   Google Scholar
• Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Hypersensitivity. 2013;68(10):1219–1232.
   Google Scholar
• Mertes PM, Malinovsky JM, Jouffroy L, et al. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol. 2011;21(6):442–453.
   PubMed Web of Science ®Google Scholar
• Romano A, Gaeta F, Valluzzi RL, et al. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Hypersensitivity Clin Immunol. 2010;126(5):994–999.
   Web of Science ®Google Scholar
• Romano A, Gaeta F, Valluzzi RL, et al. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of alternative cephalosporins. J Hypersensitivity Clin Immunol. 2015;136(3):685.e3–691.e3.
   Google Scholar
• Ortega N, Doña I, Moreno E, et al. Practical guidelines for diagnosing hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. J Investig Allergol Clin Immunol. 2014;24(5):308–323.
   PubMed Web of Science ®Google Scholar
• Blanca-Lopez N, Perez-Alzate D, Andreu I, et al. Immediate hypersensitivity reactions to ibuprofen and other arylpropionic acid derivatives. Hypersensitivity. 2016;71(7):1048–1056.
   Google Scholar
• Lobera T, Audícana MT, Alarcón E, et al. Hypersensitivity to quinolones: low cross-reactivity to levofloxacin. J Investig Allergol Clin Immunol. 2010;20(7):607–611.
   PubMed Web of Science ®Google Scholar
• González I, Lobera T, Blasco A, et al. Immediate hypersensitivity to quinolones: moxifloxacin cross-reactivity. J Investig Allergol Clin Immunol. 2005;15(2):146–149.
   PubMed Web of Science ®Google Scholar
• Kepil Özdemir S, Öner Erkekol F, Ünal D, et al. Management of hypersensitivity reactions to proton pump inhibitors: a retrospective experience. Int Arch Hypersensitivity Immunol. 2016;171(1):54–60.
   PubMed Web of Science ®Google Scholar
• Mertes P-M, Laxenaire MC. Adverse reactions to neuromuscular blocking agents. Curr Allergy Asthma Rep. 2004;4(1):7–16.
   PubMed Web of Science ®Google Scholar
• Cernadas JR, Brockow K, Romano A, et al. General considerations on rapid desensitization for drug hypersensitivity – a consensus statement. Hypersensitivity. 2010;65:1357.
   Google Scholar
• Scherer K, Brockow K, Aberer W, et al. Desensitization in delayed drug hypersensitivity reactions – an EAACI position paper of the Drug Hypersensitivity Interest Group. Hypersensitivity. 2013;68:844.
   Google Scholar
• Teraki Y, Shiohara T. Successful desensitization to fixed drug eruption: the presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization. Dermatology. 2004;209:29–32.
   PubMed Web of Science ®Google Scholar
• Schmidt D, Kluge W. Fatal toxic epidermal necrolysis following reexposure to phenytoin: a case report. Epilepsia. 1983;24:440–443.
   PubMed Web of Science ®Google Scholar
• Lam A, Randhawa I, Klaustermeyer W. Cephalosporin induced toxic epidermal necrolysis and subsequent penicillin drug exanthem. Allergol Int. 2008;57:281–284.
   PubMedGoogle Scholar
• Williams B, Hanson A, Sha B. Diffuse desquamating rash following exposure to vancomycin-impregnated bone cement. Ann Pharmacother. 2014;48(8):1061–1065.
   PubMed Web of Science ®Google Scholar
• Paulmann M, Mockenhaupt M. Unintended rechallenge: generalized bullous fixed drug eruption in two elderly women. Hautarzt. 2017;68(1):59–63. (In German).
   PubMed Web of Science ®Google Scholar
• Dwyer DF, Barrett NA, Austen KF; Immunological Genome Project Consortium. Expression profiling of constitutive mast cells reveals a unique identity within the immune system. Nat Immunol. 2016;17:878–887.
   PubMed Web of Science ®Google Scholar
• Castells M. Diagnosis and management of anaphylaxis in precision medicine. J Allergy Clin Immunol. 2017;140(2):321–333.
   PubMed Web of Science ®Google Scholar